• 1
    Gowing L., Farrell M., Bornemann R., Sullivan L. E., Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; 2: Art. No. CD004145. DOI:10.1002/14651858.CD004145.pub3.
  • 2
    Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105: 84459.
  • 3
    Day C., Haber P. S. Managing drug dependence in people with hepatitis C. In: Dore G. J., Temple-Smith M., editors. Hepatitis C: An Expanding Focus. Melbourne: IP Communications; 2009, p. 288307.
  • 4
    Turner K. M. E., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 197888.
  • 5
    Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 145462.
  • 6
    Sharma M., Burrows D., Bluthenthal R. Coverage of HIV prevention programmes for injection drug users: confusions, aspirations, definitions and ways forward. Int J Drug Policy 2007; 18: 928.
  • 7
    Farrell M., Ward J., Mattick R. P., Hall W., Stimson G. V., Des Jarlais D. et al. Fortnightly review: methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309: 9971001.
  • 8
    Mathers B. M., Degenhardt L., Hammad A., Wiessing L., Hickman M., Mattick R. P. et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 101428.
  • 9
    Topp L., Day C. A., Iversen J., Wand H., Maher L. Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995–2009. AIDS 2011; 25: 83542.
  • 10
    Kwon J. A., Iversen J., Maher L., Law M. G., Wilson D. P. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr 2009; 51: 4629.
  • 11
    Ritter A., Chalmers J. Polygon: the many sides to the Australian opioid pharmacotherapy maintenance system. Report no.: ANCD Research Paper 18. Canberra: Australian National Council on Drugs; 2009.
  • 12
    Guyatt G., Oxman A. D., Akl E. A., Kunz R., Vist G., Brozek J. et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 38394.
  • 13
    Hawkins N. G., Sanson-Fisher R. W., Shakeshaft A., D'Este C., Green L. W. The multiple baseline design for evaluating population-based research. Am J Prev Med 2007; 33: 1628.
  • 14
    Brown C. A., Lilford R. J. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006; 6: 54.
  • 15
    Rychetnik L., Frommer M., Hawe P., Shiell A. Criteria for evaluating evidence on public health interventions. J Epidemiol Commun Health 2002; 56: 11927.